

Date: September 02, 2024

BSE Limited P J Towers, Dalal Street, Mumbai – 400 001 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find attached the presentation for the information of investors.

The presentation is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

Pradeep Chugh Company Secretary and Compliance Officer

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600 CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com

MANKIND PHARMA LIMITED

Mankind ||| >

INVESTOR PRESENTATION -

Key Credit Highlights Sep'24



Safe Harbour Statement



The statements, are as on date and may contain forward-looking statements like the words "believe", "expects", "anticipate", "aim", "will likely result", "would", "will continue", "contemplate" "intends", "plans", "estimates", "seek to", "future", "objective", "projects", "goal", "likely", "project", "should", "potential" "will", "may", "targeting" or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.

The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, the Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.



Index

Company Overview

- History and Key Milestones
- At a Glance
- **Core Competencies**
- 5 Stage Journey
- Strategy Going Ahead

В

А

Acquisition Overview & Rationale

- **Transaction Overview**
- BSV: At a Glance
- High Entry Barrier Portfolio Limited Competition
- BSV: Comprehensive Portfolio with Strong Moats in Fast-Growing Industry
- Leadership in WH (#1 in Gynae) Led by Complementary Portfolio ٠
- BSV: Specialty Branded Portfolio in International Markets
- BSV's acquisition to add super specialty portfolio
- Sales Mix with Strong EBITDA Margins is Favorable for Mankind


D

Key Credit Highlights

- Consistent outperformance with financial prudence
- Uniquely positioned in high growth domestic market
- Highly diversified business with multiple derisking levers in place
- State-of-the-art manufacturing and R&D capabilities
- **Robust Corporate Governance**

Appendix

- Q1 FY25 P&L Highlights
- **Reference Documents**
- Annexures






Company Overview

Mankind Pharma – History and Key Milestones








Mankind has Primarily Grown Organically and is the Youngest amongst the Top 5 Pharmaceutical Companies in India in terms of Domestic Sales in FY24.

Mankind Pharma - at a Glance



- Commenced operations in 1995, Mankind Pharma Limited is India's 4th largest pharmaceutical company by domestic sales, and 2nd largest in terms of sales volume
- The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products:
 - Pharmaceuticals Portfolio catering to 10+ acute & chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN, respiratory, etc.
 - Consumer Healthcare (Forayed in 2007) Several differentiated brands in condoms, pregnancy detection, antacid powders, vitamin and mineral supplements, oral contraceptives, anti-acne preparations categories, etc.
- Market Leading Presence:
 - #1 rank in prescriptions over the last 7 years;
 - >2x avg. volume growth vs IPM (FY18-24);
 - 4 consumer healthcare brands ranked #1 in their respective categories
- Expansive Distribution Network One of the largest field force of 16,000+ catering to 5+ lakh doctors



		Serving 2
B	usiness Snapshot (FY24))
INR 10,335 Cr Revenue	INR 2,550 Cr EBITDA	24.7% EBITDA Margin
<mark>18.5%</mark> Revenue CAGR FY21-24	15.4% EBITDA CAGR FY 21-24	92% Domestic Revenue
Nil / INR 3,260 Cr Net Debt / Cash	23 Brand families ³ worth INR 100 Cr+	30+ Manufacturing and R&D facilities
~INR 99,100 Cr Market Cap ¹	>80% CFO/ EBITDA ratio (FY24)	AA+ Credit Rating (CRISIL/ICRA)
18.8% PAT Margin	34.0% ROCE ²	28.9% ROE ²

Source: Company, IQVIA; Note: 1. Basis market cap as of 30 August 2024; 2. Refer Annexure for Formulae; 3: As per IQVIA; TTM March 2024


Execution Excellence led by Core Competencies











Strategy Going Ahead



Increase the value of prescriptions in existing markets of strength by expanding market coverage; CVM moved from 62% in FY21 to 69% in FY24



Increasing share of chronic segment by growing presence in existing therapies (Diabetes - Insulin Glargine, Respiratory – Inhalers) and expansion into new therapies like CNS, Transplant, Urology, Oncology



Increase penetration in Metros/Tier I cities by engaging Key Opinion Leaders, hospital tie-ups and specialty division launches (10+ divisions launched in last 3 years)



International DMF Quality API, introducing DMF quality medicines at Indian prices (160+ SKUs launched till date)



Expand from mass market and consumer healthcare to specialty chronic and super specialty high entry barrier businesses



Pursue in-organic growth via M&A and in-licensing with a focus on high entry barrier markets in Chronic, Consumer Healthcare segment, and other Healthcare adjacencies

Grow consumer healthcare business through line extensions, new launches, and premiumization, by leveraging existing brand equity, additional distribution models, Rx to OTx to OTC



Continue to develop digital platforms to enhance doctor engagement medical content; end-to-end business transformation through AI/ML based technologies to improve productivity and efficiency




Acquisition Overview & Rationale



		Transaction Su	ımmary						
BSV Overview	 BSV is a Leading Branded Specialty Pharma Platform in Women's Health and Critical care with huge opportunity in both India and International Markets 								
Transaction Details	 Mankind to acquire¹100% stake in BSV Enterprise value of approx. INR 13,630 Cr Translates to 22x-23x EBITDA FY25E Expected synergy benefits ranging from Rs 50 - 100 Cr over 12 to 24 months Translates to 17x-18x EBITDA FY26E 								
Transaction Funding	 To be funded through internal accruals and a mix of debt and equity Net debt / EBITDA to be not more than 2x by FY26E 								
Impact on Financials	 2nd full year onwards - EPS accretive Expect strong sustained double digit top line growth and adjusted EBITDA margin of 30%+ 								
Transaction Timelines	 Definitive agree 	eements signed; Transactio	on expected to close in	3-4 months					
	BSV's Acqui	sition is in-line with	our Stated Acquis	ition Thesis					
High Entry Barrier Portfolio	R&D Decialty Tech Platform	Complementary Portfolio	EBITDA Margin Accretive	✓ Net debt/ EBITDA <2x by FY26	Unlock Synergies				







Specialized pharma player shaping the Women Health and Fertility therapies in India and Emerging Markets

- Notes:
 - Brands classified on the basis of India sales in FY24


2. Sales CAGR is for the period FY21-24 where-in revenues are pro forma for acquisitions and adjusted for discontinued products and Covid-19

EBITDA adjusted for acquisition/exit related cost, ESAR and other one-time expenses in FY24

High Entry Barrier Portfolio - Limited Competition




BSV Market Share - Domestic (FY24)



BSV: Comprehensive Portfolio with Strong Moats in Fast-Growing Industry





& expected to reach \$ 60B by 2030

Source: Market and Industry data as per WHO

Leadership in WH (#1 in Gynae) Led by Complementary Portfolio



BSV

 $\checkmark\checkmark$

 $\checkmark\checkmark$

 $\checkmark \checkmark \checkmark$

 $\checkmark\checkmark$

BSV

~1.2K FF

20K

28K

Mankind

 $\sqrt{\sqrt{\sqrt{}}}$

 \checkmark

 \checkmark

Coverage Expansion


Mankind

~16K FF

100K

41K

add value to BSV portfolio



2.	Based on FY24 India sales

3. Basis state government & other govt. agency reach

Source: IQVIA last 12 months Mar-24 MAT sales; All numbers in INR crore Notes:

BSV IQVIA product sales reclassified according to targeted therapeutic area of Women Health -1. Specialty, Rx and Fertility


BSV: Specialty Branded Portfolio in International Markets



Revenues	\$77m International Business Revenue ¹ (FY21-24 Revenue CAGR - 25% in cc terms)						
Geographic Spread	2 Home Markets Established - • ASEAN • MENA Philippines and Malaysia • LATAM • RCIS						
Brands and TA Focus	Focused presence across 7 brand families Increasing focus on fertility						
S&M and Market Access	260+ Field Force strength on-ground across 15 countries 20 member medico-marketing team (Complex portfolio with demand in Hospital and Institutions trade channel)						
Regulatory Excellence	Regulatory capabilities to enter attractive EMs with higher regulatory barriers						
In-Licensing	Expanded portfolio via in-licensing (25+ deals till date)						

BSV's acquisition¹ to add super specialty portfolio





Mankind has consistently evolved having a comprehensive portfolio across the pharma value chain

Sales Mix with Strong EBITDA Margins is Favorable for Mankind

FY24	MankindIII>	BSV	Pro-forma company
INR cr	Serving-Life	bringing life to life	
Revenue	10,335	1,723	12,058
(y-o-y Growth)	+18%	+20%	
Revenue Mix %	International	International	International
	8%	46%	13%
	Domestic	Domestic	Domestic
	92%	54%	87%
Brand Families (>INR 50cr)	40	10	50
EBITDA	2,550	489 ¹	3,039
EBITDA Margin %	24.7%	28.4%	25.2%


Mankind



Key Credit Highlights

Key Credit Highlights







Resilient and Profitable Growth Trajectory




21




EBITDA (INR Cr.) and Margin %¹





PAT (INR Cr.) and Margin %




Source: Company; Note 1. EBITDA refers to profit for the year/period, as adjusted to exclude (i) other income, (ii) depreciation and amortization expenses, (iii) finance costs and (iv) total tax expense. EBITDA Margin refers to the percentage margin derived by dividing EBITDA by revenue from operations 2. Adjusted with one time M&A related expense and other non-recurring cost


... And disciplined financial prudence ...



Net Cash (INR crore)



ROE*





ROCE*

Capex (INR Crore)




Net Operating Working Capital Days





Cash Flow from Operations (INR crore)



Source: Company; Notes: * On TTM Basis; Refer Annexure for Formulas


... while consistently outperforming the IPM and IPM Chronic...





Continued outperformance to IPM driven by Volume Led Strategy

...including consistent outperformance to IPM Chronic....




... Led by outperformance in key therapeutic areas ...



High Ranks across Acute and Chronic Areas

Koy Thoropy Aroos	Revenue Share	Rank in CVM	FY 20-24 CAGR		
Key Therapy Areas	(FY24)	(FY24)	Mankind	IPM	
Chronic therapies	36%	4	15%	11%	
Acute therapies	64%	2	11%	9%	
Overall	100%	2	12%	9%	

Significant outperformance in key therapies (Cardio, Anti-Infective, Anti-Diabetic, VMN, and Gynae) in FY 20-24 CAGR



IPM Growth Rate %
Mankind Growth Rate %

Uniquely positioned with strong focus on domestic business...

#4

By Value



8% Overall revenue INR 9,522 Cr. INR 10,335 Cr. 93% 92% Pharmaceuticals Domestic Exports Consumer Healthcare Ranked Ranked Ranked #1


#2

By Volume

Segmental Break Up - FY24

2

Consistent Growth in Domestic Revenues





include Mankind Medicines¹


Source: Company, IQVIA (1) IQVIA TSA MAT Mar'24 DMF: Drug Master File API: Active Pharma Ingredients

In prescriptions

from last 7 years

... with demonstrated track record of building & scaling-up brands ...








Key Performance Highlights	FY18	FY19	FY20	FY21	FY22	FY23	FY24
Volume Share in IPM (%)	4.8	5.1	5.2	5.7	5.5	5.7	5.8
Value Growth YoY in IPM (%)	11.3	12.6	12.5	11.1	17.7	10.6	8.5
Market Share by Value in IPM (%)	3.9	4.0	4.1	4.3	4.3	4.4	4.4
Market Ranking by Value in IPM (x)	4	4	4	4	4	4	4
CVM Share in Total IPM (%)	60.2	61.6	62.4	62.2	65.4	68.1	68.8
Market Share in Covered Market (%)	6.6	6.5	6.5	6.9	6.6	6.5	6.4
Covered Market Rank by Volume (x)	2	2	2	2	2	2	2
Market Ranking by Volume in IPM (x)	5	3	3	3	3	3	3
Chronic Share in Total Portfolio (%)	27.9	31.9	32.2	34.1	32.9	33.9	35.5
Chronic Growth YoY (%)	16.4	28.6	13.5	17.6	13.6	14.1	13.5
Metro & Class 1 Share (%)	49.9	49.2	48.1	51.8	52.9	53.2	53.0

... with Differentiated marketing strategy with leading OTC brands






Diversified business model with multiple derisking levers in place ...




Diversified Therapy Presence






With increasing share of revenues from chronic therapies



Diversified presence via scale up in Consumer Healthcare (OTC)



Focus on further strengthening key brands like Manforce, Gas-O-Fast and Prega News[®] through premiumization, and line-extensions






Took just 29 years to scale brands vs multiple decades taken by peers

... With a Pan-India diversified coverage of doctors and field force ...






Unique company having deeper penetration in metros as well as the remotest part of the country

... With Brands across Business Verticals ...





... And Expanding to Specialty Products Portfolio Inorganically also ...



Therapy Area	Brand Launched (Year)	Indication	Reference Market Size (INR Cr)	Market 5 Year CAGR	Rationale
Ke	Neptaz # (2023)	Heart Failure	626 ¹	21%	• Neptaz – In-licensed from Novartis . Strong Revenue and Volume growth. Ranks in the top 5 in its market.
CARDIAC	CRENZLO # (2024)	High LDL Cholesterol	5,576	12%	 Crenzlo - In-licensed from Novartis, to foray into the latest generation lipid-lowering injectables through the patented drug 'Inclisran'.
ANTI-DIABETIC	Nobeglar [®] # (2023)	C Type 1 and 2 Diabetes	4,450	6%	 In-licensed from Biocon, to foray in niche insulin category. Launch of the year, with 1 lakh+ prescriptions within one year.
RESPIRATORY	Combihale * (2022) Symbicort * (2024)	Chronic Obstructive Pulmonary Disease (COPD)	4,596	14%	 Combihale - acquired from DRL, to foray into the rapidly growing inhaler market. Symbicort - Exclusive distribution agreement with AstraZeneca for India, marking our entry into the premium inhalation segment.
DERMA	Daffy * (2022)	Paediatric Skin and Hair care	2,665	15%	 Daffy, acquired from DRL, strong growth continues since its acquisition in 2022. Foray into the infant skin and hair care category within the emollients section growing by 1.5X of IPM over the last 5 years.
ASTRO INTESTINAL	VONATIME VONALONG # (2024)	Gastroesop hageal Reflux Disease (GERD)	8,064	8%	 Vonoprazan - In-licensed from Takeda, we aim to improve the quality of life for those suffering from acid-related illnesses. GERD prevalence in the Indian population is ~8.2%, with a higher prevalence of around 11.1% in the urban population.
	Fora	y into Onco and 1	Fransplant bus	iness through	acquisition of Panacea


1. Molecule Market Size for Neptaz, all others are at Group level; # In-licensed ;* Acquired

4

State of the Art Manufacturing and R&D facilities



75% in-house manufacturing has enabled more control over quality, delivery timelines, and Supply Chain Management



Global Accreditations USFDA, WHO GMP, EU GMP, ANVISA, Peru Audit, FDA Philippines, National Drug Authority of Uganda, ZMRA Zambia, TMDA Tanzania, ISO 14001:2015, ISO 45001:2018 Among Others

Robust Corporate Governance



Experienced Board of Directors leading with transparency and accountability and operating with integrity and ethics

Work experience







10-20 vears



Mr. Surendra Lunia serves as an Independent Director of the Company and has been with the Company since February 2015. He holds a Bachelors degree in Commerce from St. Xavier's College, Calcutta. He is a member of the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India.

Profile of Independent Directors



Mr. T. P. Ostwal serves as an Independent Director of the Company and has been with the Company since January, 2020. He is a member of the ICAI and a senior partner of chartered accounting firms T.P. Ostwal & Associates LLP and DTS & Associates LLP.




Ms. Vijaya Sampath serves as an Independent Director of the Company and has been with the Company since August 2022. She holds a Bachelor Degree in Arts in English literature from the University of Madras. Chennai and a Bachelor's degree in Law from the University of Mysore, Karnataka. She is a fellow member of the Institute of Company Secretaries of India



Mr. Bharat Anand serves as an Independent Director of the Company and has been with the Company since August 2018. He holds a Bachelor Degree in Arts (Economics) from the University of Delhi and a Bachelor's degree in Law (Honours) from Jesus College, Cambridge University. Mr. Anand is a Partner of Khaitan & Co, LLP.



Mr. Vivek Kalra serves as an Independent Director of the Company and has been with the Company since August 2022. He holds a Bachelor Degree in Technology (Electrical Engineering) from Indian Institute of Technology, Bombay and an MBA from Leland Stanford Junior University.





Risk

Management



Audit



Nomination &

Remuneration



Stakeholders'

Relationship



Continuous guidance of Board of Directors and internal committees enable Mankind to abide by ethical standards, and operate with integrity & transparency

Experienced Promoter Group and Senior Management



Seasoned Whole Time Directors



5

Mr. Ramesh Juneja **Chairman & Whole Time Director**

- Founder of Mankind Group with over 33 years of experience in the pharmaceutical industry
- Awarded "Entrepreneur of the Year" 2023. Economic Times Awards for Corporate Excellence
- He championed low-cost generics, making essential drugs accessible to a vast segment of the Indian population



Mr. Raieev Juneia Vice chairman & Managing Director

- He brings extensive industry experience spanning over 30 vears and his deep understanding of the pharmaceutical industry drives the company's success
- He is responsible in crafting and executing a compelling vision - to place Mankind Pharma among the top three companies with a strong market presence in OTC and chronic segments



Mr. Sheetal Arora Chief Executive Officer & Whole Time Director

- Over 25 years of experience in the pharma sector
- His strategy is to achieve right blend of generic and niche products for global markets and nurture a team of professionals who can implement his vision



Mr. Satish Kumar Sharma Whole Time Director

- Has been with the Company since September 2016.
- He has 16+ years of experience in the pharma sector
- He holds a Bachelor's degree in Pharmacy from Gulbarga University, Karnataka.

Well Qualified and Experienced Senior Management Team								
Mr Arjun Juneja	Mr Prem Kumar Arora	Mr Chanakya Juneja	Dr Anil Kumar	Dr Sanjay Koul				
Chief Operating Officer	Director-FHA	Director-Technology	Chief Scientific Officer	Chief Marketing Officer				
Mr Ashutosh Dhawan	Mr Atish Majumdar	Mr Prakash Agarwal	Mr Pradeep Chugh					
Chief Financial Officer	Sr President-Marketing	President-Strategy	Company Secretary	35				



Appendix




INR Crore	Q1FY25	Q1FY24	YoY Growth	Q4FY24	QoQ Growth	FY24	FY23	YoY Growth
Revenue from Operations (A=B+C)	2,893	2,579	12.2%	2,441	18.5%	10,335	8,749	18.1%
Domestic Business (B)	2,634	2,419	8.9%	2,174	21.2%	9,522	8,453	12.6%
i. Domestic Business (ex CH)	2,428	2,211	9.8%	2,018	20.3%	8,816	7,761	13.59%
ii. Consumer Healthcare (CH)	206	208	-0.9%	156	32.0%	706	692	2.0%
Exports Business (C)	259	160	61.9%	267	-3.0%	813	296	174.7%
Gross Profit	2,081	1,759	18.3%	1,704	22.1%	7,125	5,836	22.1%
EBITDA	686	660	4.0%	594	15.5%	2,550	1,913	33.3%
Profit After Tax	543	494	9.9%	477	13.9%	1,942	1,310	48.2%
Diluted EPS ¹ (INR)	13.4	12.1	10.1%	11.7	13.9%	47.7	32.0	49.0%
Cash EPS ¹ (INR)	16.1	14.3	12.1%	14.4	11.8%	57.6	40.1	43.6%
Gross Margins %	71.9%	68.2%	370 bps	69.8%	210 bps	68.9%	66.7%	220 bps
EBITDA Margins %	23.7%	25.6%	(190 bps)	24.3%	(60 bps)	24.7%	21.9%	280 bps
Adj. EBITDA Margins % ²	25.2%	25.6%	(40 bps)	24.3%	90 bps	24.7%	21.9%	280 bps
PAT Margins %	18.8%	19.2%	(40 bps)	19.5%	(70 bps)	18.8%	15.0%	380 bps

1. Diluted EPS and Cash EPS not annualised; 2. Adjusted with one time M&A related expense and other non-recurring cost







Annual Report FY24



BSV Presentation



Q1FY25 Presentation



Investor Presentation Aug'24



Annexures



- **ROE** = (Profit for the year) / (average total equity less cash)
 - o Profit excludes interest income and gain on current investments measured at FVTPL
- Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash)
 - o Profit excludes any M&A related impact, interest income and gain on current investments measured at FVTPL
 - Adjusted total equity excludes Cash, cash used for acquisitions and is adjusted for M&A related impact (net of Tax)
- ROCE = (EBIT for the year) / (Capital employed less cash)
 - EBIT excludes other income
 - Capital employed is the sum of total equity, total borrowings, total lease liabilities and deferred tax liabilities (net) less deferred tax assets and Cash.
- Adjusted ROCE = (Adjusted EBIT for the year)/ (Adjusted Capital employed less cash)
 - Adjusted EBIT excludes M&A related impact and other income
 - Adj. Capital employed is the sum of total equity, total borrowings, total lease liabilities, deferred tax liabilities (net), M&A related impact (net of Tax) less deferred tax assets, Cash and cash used for acquisitions.
- **Cash** = (Cash and cash equivalents + Other bank balances + investment in Mutual funds)
- Net Cash = (Cash Current borrowings Non Current borrowings at the end of the year)
- Net Operating Working Capital Days = (Average operating working capital / Revenue from operations) X 365 days.
 Operating working capital is the sum of Inventories and Trade receivables less Trade payables
- Cash EPS = Profit/(Loss) for the period plus Depreciation, Amortization and Impairment / weighted average number of equity shares outstanding during the period

Thank You

For more information please visit our website: https://www.mankindpharma.com

For specific queries, contact:

Abhishek Agarwal Investor Relations - 011 - 46846700 Ext. 3532 Investor.relations@mankindpharma.com